ABSTRACT
Urticaria is a disease characterized by wheals and/or angioedema. Chronic spontaneous urticaria (CSU) occurs for longer than 6 weeks and appears independently of any identifiable exogenous stimulus. During the vaccination campaign for Coronavirus disease 2019 (COVID-19) pandemic, several cutaneous adverse events have been described, among which urticaria lasting less than 6 weeks (acute urticaria, AU). AU due to vaccines can be IgE or non-IgE mediated; the former typically develop within 4 h of drug exposure, the latter occurs later and the mechanism is unclear. In this retrospective study we analyzed the frequency and clinical characteristics of urticaria occurring after COVID-19 vaccine (post-vaccination urticaria relapse) in adult CSU patients treated with antihistamine and omalizumab, and in clinical remission.
Subject(s)
Anti-Allergic Agents , COVID-19 , Chronic Urticaria , Urticaria , Adult , Humans , Omalizumab/adverse effects , Chronic Urticaria/drug therapy , COVID-19 Vaccines/adverse effects , Retrospective Studies , RNA, Messenger , Anti-Allergic Agents/adverse effects , Urticaria/etiology , Urticaria/chemically induced , Histamine Antagonists/adverse effects , Chronic Disease , Recurrence , Treatment OutcomeSubject(s)
COVID-19 , Telemedicine , Tinea , Humans , COVID-19/epidemiology , Pandemics , Tinea/diagnosis , Tinea/drug therapy , Tinea/epidemiology , Italy/epidemiologyABSTRACT
Telemedicine can be defined as a modern technology supporting health care from a distance [...].
Subject(s)
COVID-19 , Exanthema , Pityriasis Rosea , COVID-19 Vaccines , Humans , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , VaccinationABSTRACT
The COVID 19 vaccination campaign has been underway for about a year now, and there are now many skin reactions associated with the administration of these vaccines in the literature. In view of the forthcoming third dose, we believe it is important to report our experience.